2015 Q2 Form 10-K Financial Statement
#000114420416124276 Filed on September 16, 2016
Income Statement
| Concept | 2015 Q2 | 2015 | 2014 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $1.050M | $3.400M | $3.540M |
| YoY Change | -33.96% | -3.95% | 53.91% |
| % of Gross Profit | |||
| Research & Development | $1.390M | $3.660M | $5.132M |
| YoY Change | -36.82% | -28.67% | 19.53% |
| % of Gross Profit | |||
| Depreciation & Amortization | $140.0K | $294.2K | $203.2K |
| YoY Change | 180.0% | 44.77% | -3.62% |
| % of Gross Profit | |||
| Operating Expenses | $2.440M | $7.063M | $8.667M |
| YoY Change | -35.62% | -18.51% | 31.52% |
| Operating Profit | -$7.063M | -$8.667M | |
| YoY Change | -18.51% | 31.52% | |
| Interest Expense | $1.830M | $2.650M | $3.093M |
| YoY Change | -230.71% | -14.32% | 221.29% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$310.0K | $4.865M | -$4.934M |
| YoY Change | 106.67% | -198.6% | 115.91% |
| Pretax Income | -$920.0K | -$2.198M | -$13.60M |
| YoY Change | -82.77% | -83.84% | 53.25% |
| Income Tax | $0.00 | $0.00 | $0.00 |
| % Of Pretax Income | |||
| Net Earnings | -$920.0K | -$2.198M | -$13.60M |
| YoY Change | -82.77% | -83.84% | 53.25% |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | -$0.04 | -$0.27 | |
| Diluted Earnings Per Share | -$321.7K | -$0.09 | -$0.27 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 57.15M shares | 56.55M shares | 51.23M shares |
| Diluted Shares Outstanding | 59.22M shares | 51.23M shares |
Balance Sheet
| Concept | 2015 Q2 | 2015 | 2014 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $31.47M | $31.47M | $36.70M |
| YoY Change | -14.25% | -14.26% | 163.65% |
| Cash & Equivalents | $31.47M | $31.47M | $36.70M |
| Short-Term Investments | |||
| Other Short-Term Assets | $0.00 | $214.4K | $260.0K |
| YoY Change | -100.0% | -17.53% | -56.67% |
| Inventory | |||
| Prepaid Expenses | $214.4K | ||
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $31.68M | $31.68M | $36.95M |
| YoY Change | -14.27% | -14.26% | 154.48% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $11.96M | $11.96M | $5.500M |
| YoY Change | 117.63% | 117.5% | 1070.21% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | $399.7K | ||
| YoY Change | -2.09% | ||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $140.0K | $142.5K | $1.000M |
| YoY Change | -86.0% | -85.75% | 0.0% |
| Total Long-Term Assets | $12.50M | $12.50M | $6.910M |
| YoY Change | 81.1% | 80.97% | 265.61% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $31.68M | $31.68M | $36.95M |
| Total Long-Term Assets | $12.50M | $12.50M | $6.910M |
| Total Assets | $44.19M | $44.19M | $43.86M |
| YoY Change | 0.75% | 0.75% | 167.28% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $410.0K | $405.7K | $430.0K |
| YoY Change | -4.65% | -5.65% | -55.67% |
| Accrued Expenses | $28.52K | $28.52K | $90.00K |
| YoY Change | -68.95% | -68.31% | -55.0% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $0.00 | ||
| YoY Change | |||
| Total Short-Term Liabilities | $600.9K | $600.9K | $520.0K |
| YoY Change | 16.06% | 15.56% | -55.93% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $7.181M | $9.040M |
| YoY Change | -100.0% | -20.56% | 160.52% |
| Other Long-Term Liabilities | $4.620M | $4.619M | $10.94M |
| YoY Change | -57.77% | -57.78% | 191.73% |
| Total Long-Term Liabilities | $11.80M | $11.80M | $19.98M |
| YoY Change | -40.92% | -40.94% | 176.73% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $600.9K | $600.9K | $520.0K |
| Total Long-Term Liabilities | $11.80M | $11.80M | $19.98M |
| Total Liabilities | $12.40M | $12.40M | $20.49M |
| YoY Change | -39.48% | -39.48% | 143.93% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$54.10M | ||
| YoY Change | 4.24% | ||
| Common Stock | $57.24K | ||
| YoY Change | 4.8% | ||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $31.79M | $31.79M | $23.37M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $44.19M | $44.19M | $43.86M |
| YoY Change | 0.75% | 0.75% | 167.28% |
Cashflow Statement
| Concept | 2015 Q2 | 2015 | 2014 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$920.0K | -$2.198M | -$13.60M |
| YoY Change | -82.77% | -83.84% | 53.25% |
| Depreciation, Depletion And Amortization | $140.0K | $294.2K | $203.2K |
| YoY Change | 180.0% | 44.77% | -3.62% |
| Cash From Operating Activities | -$1.250M | -$6.212M | -$6.330M |
| YoY Change | 31.58% | -1.86% | 9.14% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$1.200M | $6.760M | $5.231M |
| YoY Change | -25.47% | 29.23% | 7956.39% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $0.00 | $1.000M | $0.00 |
| YoY Change | -100.0% | -100.0% | |
| Cash From Investing Activities | -$1.200M | -$5.760M | -$5.230M |
| YoY Change | 96.72% | 10.14% | 393.4% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 0.000 | 6.743M | 34.34M |
| YoY Change | -100.0% | -80.36% | 427.5% |
| NET CHANGE | |||
| Cash From Operating Activities | -1.250M | -6.212M | -6.330M |
| Cash From Investing Activities | -1.200M | -5.760M | -5.230M |
| Cash From Financing Activities | 0.000 | 6.743M | 34.34M |
| Net Change In Cash | -2.450M | -5.229M | 22.78M |
| YoY Change | -171.22% | -122.95% | -6608.57% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$1.250M | -$6.212M | -$6.330M |
| Capital Expenditures | -$1.200M | $6.760M | $5.231M |
| Free Cash Flow | -$50.00K | -$12.97M | -$11.56M |
| YoY Change | -107.58% | 12.21% | 97.12% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2016Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
58179 | USD |
| CY2015Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
44187089 | USD |
| CY2015Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
57242 | USD |
| CY2015Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-54099572 | USD |
| CY2015Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
31785867 | USD |
| CY2016 | us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
7087 | USD |
| CY2015 | us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
-63323 | USD |
| CY2016 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10724629 | USD |
| CY2016 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.19 | |
| CY2015 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.04 | |
| CY2015 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.09 | |
| CY2014 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
5131523 | USD |
| CY2015 | nnvc |
Discount On Convertible Debentures
DiscountOnConvertibleDebentures
|
1175344 | USD |
| CY2016 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
476368 | USD |
| CY2015 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
6760109 | USD |
| CY2016Q2 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
219458 | USD |
| CY2016Q2 | us-gaap |
Assets Current
AssetsCurrent
|
24381643 | USD |
| CY2016Q2 | us-gaap |
Assets
Assets
|
36633418 | USD |
| CY2016Q2 | us-gaap |
Accounts Payable Trade Current
AccountsPayableTradeCurrent
|
96524 | USD |
| CY2016Q2 | us-gaap |
Liabilities
Liabilities
|
13585204 | USD |
| CY2016Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-64824201 | USD |
| CY2016Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
23048214 | USD |
| CY2016Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
36633418 | USD |
| CY2016Q2 | us-gaap |
Security Deposit
SecurityDeposit
|
3515 | USD |
| CY2015Q2 | us-gaap |
Security Deposit
SecurityDeposit
|
0 | USD |
| CY2016Q2 | us-gaap |
Other Assets
OtherAssets
|
99541 | USD |
| CY2015Q2 | us-gaap |
Other Assets
OtherAssets
|
142531 | USD |
| CY2016Q2 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
5474737 | USD |
| CY2015Q2 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
0 | USD |
| CY2016Q2 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
203030 | USD |
| CY2015Q2 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
0 | USD |
| CY2014 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3535849 | USD |
| CY2014 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
-1443200 | USD |
| CY2014 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-4934244 | USD |
| CY2014 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-13601616 | USD |
| CY2014 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2014 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.27 | |
| CY2014 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.27 | |
| CY2014 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
51225622 | shares |
| CY2014 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
51225622 | shares |
| CY2016 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3830531 | USD |
| CY2015 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3402778 | USD |
| CY2016 | us-gaap |
Operating Expenses
OperatingExpenses
|
8859501 | USD |
| CY2015 | us-gaap |
Operating Expenses
OperatingExpenses
|
7063100 | USD |
| CY2016 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-8859501 | USD |
| CY2015 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-7063100 | USD |
| CY2016 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
62638 | USD |
| CY2015 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
160859 | USD |
| CY2016 | us-gaap |
Interest Expense
InterestExpense
|
1042470 | USD |
| CY2015 | us-gaap |
Interest Expense
InterestExpense
|
2649592 | USD |
| CY2016 | nnvc |
Discount On Convertible Debentures
DiscountOnConvertibleDebentures
|
1427218 | USD |
| CY2016 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
541922 | USD |
| CY2015 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
8529005 | USD |
| CY2015 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
4864928 | USD |
| CY2015 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-2198172 | USD |
| CY2016 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2015 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2015 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2198172 | USD |
| CY2015 | nnvc |
Common Shares Issued For Interest
CommonSharesIssuedForInterest
|
-1502870 | USD |
| CY2016 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
57669472 | shares |
| CY2016 | us-gaap |
Depreciation
Depreciation
|
651275 | USD |
| CY2016 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.19 | |
| CY2016 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
57669472 | shares |
| CY2015 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
56553848 | shares |
| CY2015 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
59220515 | shares |
| CY2014 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
171001 | USD |
| CY2015 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
279363 | USD |
| CY2016 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
345589 | USD |
| CY2015 | us-gaap |
Depreciation
Depreciation
|
294217 | USD |
| CY2015 | us-gaap |
Adjustment For Amortization
AdjustmentForAmortization
|
8521 | USD |
| CY2016 | us-gaap |
Adjustment For Amortization
AdjustmentForAmortization
|
8270 | USD |
| CY2015 | nnvc |
Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
|
8529005 | USD |
| CY2015 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
106336 | USD |
| CY2015 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-6212332 | USD |
| CY2016 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-6829195 | USD |
| CY2015 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
6743297 | USD |
| CY2016 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
0 | USD |
| CY2015 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-5229144 | USD |
| CY2016 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-7305563 | USD |
| CY2015 | us-gaap |
Interest Paid
InterestPaid
|
980000 | USD |
| CY2016 | us-gaap |
Interest Paid
InterestPaid
|
1036115 | USD |
| CY2015 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
0 | USD |
| CY2016 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
0 | USD |
| CY2015 | us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
1152297 | USD |
| CY2016 | us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
0 | USD |
| CY2014Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
36696892 | USD |
| CY2016 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-46505 | USD |
| CY2016 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
1427218 | USD |
| CY2015 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
1175344 | USD |
| CY2015 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
-286930 | USD |
| CY2015 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
142531 | USD |
| CY2016 | nnvc |
Common Shares Issued For Interest
CommonSharesIssuedForInterest
|
-660000 | USD |
| CY2015 | us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
500000 | USD |
| CY2016 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
7007 | USD |
| CY2016 | us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
-166666 | USD |
| CY2016 | nnvc |
Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
|
541922 | USD |
| CY2016 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
5033 | USD |
| CY2016 | nnvc |
Common Stock Issued Upon Exercise Of Stock Options
CommonStockIssuedUponExerciseOfStockOptions
|
313 | USD |
| CY2015 | nnvc |
Common Stock Issued Upon Exercise Of Stock Options
CommonStockIssuedUponExerciseOfStockOptions
|
0 | USD |
| CY2016 | us-gaap |
Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
|
332476 | USD |
| CY2015 | us-gaap |
Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
|
0 | USD |
| CY2016 | us-gaap |
Proceeds From Collection Of Advance To Affiliate
ProceedsFromCollectionOfAdvanceToAffiliate
|
0 | USD |
| CY2015 | us-gaap |
Proceeds From Collection Of Advance To Affiliate
ProceedsFromCollectionOfAdvanceToAffiliate
|
1000000 | USD |
| CY2016 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-476368 | USD |
| CY2015 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-5760109 | USD |
| CY2015 | nnvc |
Issuance Of Series C Debenture For Deposit Received
IssuanceOfSeriesCDebentureForDepositReceived
|
5000000 | USD |
| CY2015 | nnvc |
Bifurccation Of Embedded Derivative
BifurccationOfEmbeddedDerivative
|
1879428 | USD |
| CY2016 | nnvc |
Issuance Of Series C Debenture For Deposit Received
IssuanceOfSeriesCDebentureForDepositReceived
|
0 | USD |
| CY2016 | nnvc |
Bifurccation Of Embedded Derivative
BifurccationOfEmbeddedDerivative
|
0 | USD |
| CY2014 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
434861 | USD |
| CY2014 | us-gaap |
Depreciation
Depreciation
|
203234 | USD |
| CY2014 | us-gaap |
Adjustment For Amortization
AdjustmentForAmortization
|
8775 | USD |
| CY2015 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
6512390 | shares |
| CY2015Q2 | us-gaap |
Leasehold Improvements Gross
LeaseholdImprovementsGross
|
7905938 | USD |
| CY2015Q2 | nnvc |
Office Equipment Gross
OfficeEquipmentGross
|
65241 | USD |
| CY2015Q2 | us-gaap |
Furniture And Fixtures Gross
FurnitureAndFixturesGross
|
1400 | USD |
| CY2015Q2 | us-gaap |
Fixtures And Equipment Gross
FixturesAndEquipmentGross
|
5264272 | USD |
| CY2016Q2 | us-gaap |
Land
Land
|
260000 | USD |
| CY2014 | nnvc |
Common Stock Issued Upon Exercise Of Stock Options
CommonStockIssuedUponExerciseOfStockOptions
|
0 | USD |
| CY2014 | nnvc |
Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
|
-1443200 | USD |
| CY2014 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-6333626 | USD |
| CY2014 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
735624 | USD |
| CY2014 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
22773647 | USD |
| CY2014 | us-gaap |
Interest Paid
InterestPaid
|
480000 | USD |
| CY2014 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
0 | USD |
| CY2014 | us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
0 | USD |
| CY2013Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
13923245 | USD |
| CY2014 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
569495 | USD |
| CY2014 | us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
-112521 | USD |
| CY2014 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
0 | USD |
| CY2014 | nnvc |
Common Shares Issued For Interest
CommonSharesIssuedForInterest
|
-2605716 | USD |
| CY2014 | us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
0 | USD |
| CY2014 | us-gaap |
Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
|
0 | USD |
| CY2014 | us-gaap |
Proceeds From Collection Of Advance To Affiliate
ProceedsFromCollectionOfAdvanceToAffiliate
|
0 | USD |
| CY2014 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-5231094 | USD |
| CY2014 | nnvc |
Issuance Of Series C Debenture For Deposit Received
IssuanceOfSeriesCDebentureForDepositReceived
|
0 | USD |
| CY2014 | nnvc |
Bifurccation Of Embedded Derivative
BifurccationOfEmbeddedDerivative
|
0 | USD |
| CY2016 | dei |
Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
|
2000-07-25 | |
| CY2016 | us-gaap |
Business Acquisition Date Of Acquisition Agreement1
BusinessAcquisitionDateOfAcquisitionAgreement1
|
2005-05-12 | |
| CY2016 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
6616700 | shares |
| CY2016Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2016Q1 | nnvc |
Convertible Debentures Shares Reserved For Future Issuance
ConvertibleDebenturesSharesReservedForFutureIssuance
|
571433 | shares |
| CY2016 | us-gaap |
Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
|
0 | shares |
| CY2015 | us-gaap |
Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
|
2666667 | shares |
| CY2014 | us-gaap |
Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
|
0 | shares |
| CY2016 | us-gaap |
Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
|
-0.19 | |
| CY2015 | us-gaap |
Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
|
-0.09 | |
| CY2014 | us-gaap |
Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
|
-0.27 | |
| CY2016 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-10724629 | USD |
| CY2015 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-5276036 | USD |
| CY2014 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-13601616 | USD |
| CY2016 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-10724629 | USD |
| CY2015 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-2198172 | USD |
| CY2014 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-13601616 | USD |
| CY2016 | us-gaap |
Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
|
0 | USD |
| CY2015 | us-gaap |
Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
|
-3077864 | USD |
| CY2014 | us-gaap |
Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
|
0 | USD |
| CY2016 | us-gaap |
Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
|
-0.19 | |
| CY2015 | us-gaap |
Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
|
-0.04 | |
| CY2014 | us-gaap |
Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
|
-0.27 | |
| CY2015Q2 | us-gaap |
Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
|
9000000 | USD |
| CY2016Q2 | us-gaap |
Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
|
9000000 | USD |
| CY2016Q2 | us-gaap |
Leasehold Improvements Gross
LeaseholdImprovementsGross
|
7996402 | USD |
| CY2016Q2 | nnvc |
Office Equipment Gross
OfficeEquipmentGross
|
46897 | USD |
| CY2016Q2 | us-gaap |
Furniture And Fixtures Gross
FurnitureAndFixturesGross
|
5607 | USD |
| CY2016Q2 | us-gaap |
Fixtures And Equipment Gross
FixturesAndEquipmentGross
|
5302677 | USD |
| CY2015Q2 | us-gaap |
Land
Land
|
260000 | USD |
| CY2016 | us-gaap |
Other Research And Development Expense
OtherResearchAndDevelopmentExpense
|
332476 | USD |
| CY2015Q2 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
399737 | USD |
| CY2016 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Note 1 – Organization and Nature of Business</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">NanoViricides, Inc. (the “Company”) was incorporated under the laws of the State of Colorado on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> July 25, 2000</font> as Edot-com.com, Inc<b>.</b> which was organized for the purpose of conducting internet retail sales.  On April 1, 2005, Edot-com.com, Inc. was incorporated under the laws of the State of Nevada for the purpose of re-domiciling as a Nevada corporation.  On <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">May 12, 2005</font>, the corporations were merged and Edot-com.com, Inc<b>.,</b> the Nevada corporation, became the surviving entity.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On June 1, 2005, Edot-com.com, Inc. (“ECMM”) acquired Nanoviricide, Inc., a privately owned Florida corporation (“NVI”), pursuant to an Agreement and Plan of Share Exchange (the “Exchange”).  Nanoviricide, Inc. was incorporated under the laws of the State of Florida on May 12, 2005.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Pursuant to the terms of the Exchange, ECMM acquired NVI in exchange for an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80,000,000</font> newly issued shares of ECMM common stock resulting in an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font> million shares of ECMM common stock issued and outstanding.  NVI then became a wholly-owned subsidiary of ECMM. The ECMM shares were issued to the NVI shareholders on a pro rata basis, on the basis of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,000</font> shares of the Company’s common stock for each share of NVI common stock held by such NVI shareholder at the time of the Exchange.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As a result of the Exchange transaction, the former NVI stockholders held approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80</font>% of the voting capital stock of the Company immediately after the Exchange.  For financial accounting purposes, this acquisition was a reverse acquisition of ECCM by NVI, under the purchase method of accounting, and was treated as a recapitalization with NVI as the acquirer. Accordingly, the financial statements have been prepared to give retroactive effect to May 12, 2005 (date of inception), of the reverse acquisition completed on June 1, 2005, and represent the operations of NVI.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On June 28, 2005, NVI was merged into its parent ECMM and the separate corporate existence of NVI ceased.  Effective on the same date, Edot-com.com, Inc. changed its name to NanoViricides, Inc. and its stock symbol to “NNVC”, respectively.  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">NanoViricides,  Inc. (the “Company”), is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. NanoViricides is unique in the bio-pharma field in that it possesses its own state of the art facilities for the design, synthesis, analysis and characterization of the nanomedicines that we develop, as well as for production scale-up, and e-GMP-like production in quantities needed for human clinical trials. The biological studies such as the effectiveness, safety, bio-distribution and Pharmacokinetics/Pharmacodynamics on our drug candidates are performed by external collaborators and contract organizations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">   </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">We are a company with several drugs in various stages of early development. Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), to which we have the necessary exclusive licenses in perpetuity. The first agreement we executed with TheraCour on September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On February 15, 2010 the Company executed an Additional License Agreement with TheraCour.  Pursuant to the Additional License Agreement, the Company was granted exclusive licenses, in perpetuity, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes.  As consideration for obtaining these exclusive licenses, we agreed to pay a one-time licensing fee equal to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,000,000</font> shares <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(adjusted for the 3.5 to 1 reverse split)</font> of the Company’s Series A Convertible Preferred Stock (the “Series A Preferred Stock”).  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The Series A Preferred Stock is convertible, only upon sale or merger of the Company, or the sale of or license of substantially all of the Company’s intellectual property, into shares of the Company’s common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock.</font>  The Series A Preferred Stock has a preferred voting preference at the rate of nine votes per share. The Series A Preferred Stock do not contain any rights to dividends, have no liquidation preference, and are not to be amended without the Holder’s approval. The 2,000,000 shares were valued at the par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,000</font>.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2016 | dei |
Entity Incorporation State Country Name
EntityIncorporationStateCountryName
|
Colorado | |
| CY2016Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2015Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2013Q3 | nnvc |
Warrants Issued
WarrantsIssued
|
2945428 | shares |
| CY2014Q1 | nnvc |
Warrants Issued
WarrantsIssued
|
2479935 | shares |
| CY2013Q3 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
2810071 | shares |
| CY2014Q1 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
2479935 | shares |
| CY2016Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | shares |
| CY2016Q2 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
391467 | USD |
| CY2015Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | shares |
| CY2016Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
58179699 | shares |
| CY2016Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
58179699 | shares |
| CY2015Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
57242070 | shares |
| CY2015Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
57242070 | shares |
| CY2016 | us-gaap |
Business Acquisition Name Of Acquired Entity
BusinessAcquisitionNameOfAcquiredEntity
|
Edot-com.com, Inc. | |
| CY2016Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2015Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2016 | us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i><u>Reclassifications</u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results or operations.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2016 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i><u>Use of Estimates</u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheet and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, accounting for share-based compensation, accounting for derivatives and accounting for income taxes. Actual results could differ from those estimates.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2016 | us-gaap |
Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
|
42886 | USD |
| CY2015 | us-gaap |
Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
|
59675 | USD |
| CY2014 | us-gaap |
Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
|
199849 | USD |
| CY2016 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
56115 | USD |
| CY2016 | nnvc |
Software Disposal Noncash Adjustment
SoftwareDisposalNoncashAdjustment
|
26974 | USD |
| CY2015 | nnvc |
Software Disposal Noncash Adjustment
SoftwareDisposalNoncashAdjustment
|
0 | USD |
| CY2014 | nnvc |
Software Disposal Noncash Adjustment
SoftwareDisposalNoncashAdjustment
|
0 | USD |
| CY2016 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
0 | USD |
| CY2015 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
0 | USD |
| CY2014 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
5000000 | USD |
| CY2016 | us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
0 | USD |
| CY2015 | us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
0 | USD |
| CY2014 | us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
28602743 | USD |
| CY2016 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
0 | USD |
| CY2015 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
6743297 | USD |
| CY2014 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
34338367 | USD |
| CY2015Q2 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
16394801 | USD |
| CY2015Q2 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
4800186 | USD |
| CY2015Q2 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
5214064 | USD |
| CY2015Q2 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
26409051 | USD |
| CY2015Q2 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
26409051 | USD |
| CY2015Q2 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | USD |
| CY2016Q2 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
34326764 | USD |
| CY2016Q2 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
52000000 | USD |
| CY2016 | us-gaap |
Related Party Transaction Description Of Transaction
RelatedPartyTransactionDescriptionOfTransaction
|
charge its costs (direct and indirect) plus no more than 30% of direct costs | |
| CY2016 | nnvc |
Lab Supplies And Chemicals Fees
LabSuppliesAndChemicalsFees
|
25000 | USD |
| CY2016 | us-gaap |
Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
|
2000 | USD |
| CY2014Q4 | nnvc |
Acquisition And Renovation Expenses Of Manufacturing And Lab Facility
AcquisitionAndRenovationExpensesOfManufacturingAndLabFacility
|
4222549 | USD |
| CY2014Q4 | nnvc |
Closing Costs Of Facility
ClosingCostsOfFacility
|
81230 | USD |
| CY2013Q3 | nnvc |
Purchase Price Per Share
PurchasePricePerShare
|
3.50 | |
| CY2013Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2013Q3 | nnvc |
Stock Issued During Period Price Per Share
StockIssuedDuringPeriodPricePerShare
|
5.25 | |
| CY2013Q3 | us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
10308996 | USD |
| CY2013Q3 | nnvc |
Placement Agents And Attorneys Fees
PlacementAgentsAndAttorneysFees
|
618540 | USD |
| CY2013Q3 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
2945428 | shares |
| CY2014Q1 | nnvc |
Number Of Common Stock To Be Issued Upon Conversion Of Warrants
NumberOfCommonStockToBeIssuedUponConversionOfWarrants
|
75000 | shares |
| CY2014Q1 | nnvc |
Number Of Common Stock To Be Issued Upon Conversion Of Warrants
NumberOfCommonStockToBeIssuedUponConversionOfWarrants
|
25000 | shares |
| CY2014Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2014Q1 | us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
393750 | USD |
| CY2014Q1 | us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
131250 | USD |
| CY2014Q1 | nnvc |
Stock Issued During Period Price Per Share
StockIssuedDuringPeriodPricePerShare
|
5.25 | |
| CY2014Q1 | nnvc |
Warrants Exercise Price
WarrantsExercisePrice
|
6.05 | |
| CY2014Q1 | us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
20030207 | USD |
| CY2014Q1 | nnvc |
Placement Agents And Attorneys Fees
PlacementAgentsAndAttorneysFees
|
1200000 | USD |
| CY2013Q3 | nnvc |
Description Of Offering
DescriptionOfOffering
|
the Company paid the Placement Agents an aggregate cash fee representing 6% (3% each) of the gross Purchase Price paid by the Purchasers and warrants to purchase an aggregate of 2% (1% each) of the number of shares of Common Stock sold in the Offering (the Compensation Warrants) and substantially similar to the Warrants, at an exercise price equal to $5.25 per share. | |
| CY2014Q1 | nnvc |
Description Of Offering
DescriptionOfOffering
|
the Placement Agents an aggregate cash fee representing 6% of the gross Purchase Price paid by the Purchasers and warrants to purchase an aggregate of 2% of the number of shares of Common Stock sold in the Offering (the Compensation Warrants) representing two percent of the Shares and substantially similar to the Warrants, at an exercise price equal to $6.05 per share. | |
| CY2013 | nnvc |
Number Of Common Stock To Be Issued Upon Conversion Of Warrants
NumberOfCommonStockToBeIssuedUponConversionOfWarrants
|
7143 | shares |
| CY2013 | nnvc |
Stock Issued During Period Price Per Share
StockIssuedDuringPeriodPricePerShare
|
3.50 | |
| CY2014Q1 | nnvc |
Purchase Price Per Unit Description
PurchasePricePerUnitDescription
|
The price per Unit was equal to a four percent (4%) discount to the 20-day VWAP of the Companys stock price on Friday, January 17, 2014. The exercise price of the Warrant was equal to the closing price of the Companys stock on Friday, January 17, 2014. Each Unit consisted of one share of the Companys common stock, par value $0.001 per share (the Common Stock) and Sixty-Five Hundredths (65/100) of a warrant to purchase one share of Common Stock (Warrant), | |
| CY2016 | us-gaap |
Fair Value Measurements Significant Assumptions
FairValueMeasurementsSignificantAssumptions
|
a.The common stock price (post-reverse split) was in the range $2.45 to $3.90; b. 47,026,173 to 54,614,930 shares outstanding and Series A Preferred shares with 2,572 (post–split 9/10/13) issued monthly; and 169,644 issued annually to employees; c.A 5.36% premium over the common shares for the voting preferences; d. 54,506,459 to 62,208,499 total voting shares and the monthly shares representing voting rights of 0.042% to 0.484% of the total; and the annual shares representing 1.02% to 2.389% of the total; e. The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 years from 3/1/13 and a restricted term of 3.67 to 2.67 years; f. 42.87% to 27.11% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 121.97% to 265.70% volatility, 0.37% to 1.62% risk-free rate) applied to the converted common. | |
| CY2016Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
8270 | USD |
| CY2016Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
8270 | USD |
| CY2016Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
8270 | USD |
| CY2016Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
8270 | USD |
| CY2016Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
8270 | USD |
| CY2016Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
|
350117 | USD |
| CY2013Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
8009652 | USD |
| CY2014Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
23369303 | USD |
| CY2014 | nnvc |
Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued
SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued
|
2123014 | USD |
| CY2015 | nnvc |
Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued
SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued
|
852760 | USD |
| CY2016 | nnvc |
Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued
SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued
|
882386 | USD |
| CY2014 | nnvc |
Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services For August
StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServicesForAugust
|
199849 | USD |
| CY2014 | nnvc |
Common Stock Issued During Period Employee Stock Compensation Value Issued
CommonStockIssuedDuringPeriodEmployeeStockCompensationValueIssued
|
287860 | USD |
| CY2014 | nnvc |
Common Stock Shares Issued For Payment Of Debenture Interest Value
CommonStockSharesIssuedForPaymentOfDebentureInterestValue
|
2605716 | USD |
| CY2015 | nnvc |
Series Preferred Shares Value Issued For Consulting And Legal Services Rendered
SeriesPreferredSharesValueIssuedForConsultingAndLegalServicesRendered
|
24474 | USD |
| CY2015 | nnvc |
Stock Issued For Payment Of Director Fees Value
StockIssuedForPaymentOfDirectorFeesValue
|
45000 | USD |
| CY2016 | nnvc |
Stock Issued For Payment Of Director Fees Value
StockIssuedForPaymentOfDirectorFeesValue
|
45000 | USD |
| CY2014 | nnvc |
Stock Issued For Payment Of Director Fees Value
StockIssuedForPaymentOfDirectorFeesValue
|
45000 | USD |
| CY2014 | nnvc |
Common Shares And Warrants Issued Value In Connection With Private Placement Of Common Stock
CommonSharesAndWarrantsIssuedValueInConnectionWithPrivatePlacementOfCommonStock
|
30339203 | USD |
| CY2014 | nnvc |
Common Shares Issues Value To Round Up Financial Shares Arising From Private Placement
CommonSharesIssuesValueToRoundUpFinancialSharesArisingFromPrivatePlacement
|
0 | USD |
| CY2014 | us-gaap |
Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
|
83900 | USD |
| CY2015 | nnvc |
Series Preferred Shares Issued For Debenture Interest
SeriesPreferredSharesIssuedForDebentureInterest
|
1152297 | USD |
| CY2015 | nnvc |
Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services For August
StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServicesForAugust
|
59675 | USD |
| CY2015 | nnvc |
Common Stock Issued During Period Employee Stock Compensation Value Issued
CommonStockIssuedDuringPeriodEmployeeStockCompensationValueIssued
|
125003 | USD |
| CY2015 | nnvc |
Common Shares Issued In Connection With Warrant Conversion
CommonSharesIssuedInConnectionWithWarrantConversion
|
6743297 | USD |
| CY2016 | nnvc |
Common Stock Shares Issued For Payment Of Debenture Interest Value
CommonStockSharesIssuedForPaymentOfDebentureInterestValue
|
660000 | USD |
| CY2016 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
0 | USD |
| CY2016 | nnvc |
Common Stock Issued During Period Employee Stock Compensation Value Issued
CommonStockIssuedDuringPeriodEmployeeStockCompensationValueIssued
|
142589 | USD |
| CY2016 | nnvc |
Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services For August
StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServicesForAugust
|
42886 | USD |
| CY2016 | nnvc |
Adjustments To Additional Paid In Capital Warrant Issued For Debenture Interest
AdjustmentsToAdditionalPaidInCapitalWarrantIssuedForDebentureInterest
|
56115 | USD |
| CY2016 | nnvc |
Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One
StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne
|
158000 | USD |
| CY2015 | nnvc |
Common Stock Shares Issued For Payment Of Debenture Interest Value
CommonStockSharesIssuedForPaymentOfDebentureInterestValue
|
1502870 | USD |
| CY2015 | nnvc |
Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One
StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne
|
109360 | USD |
| CY2014 | nnvc |
Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One
StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne
|
102001 | USD |
| CY2014 | nnvc |
Common Shares Issued In Connection With Warrant Conversion
CommonSharesIssuedInConnectionWithWarrantConversion
|
735624 | USD |
| CY2014Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
3071986 | shares |
| CY2014Q3 | nnvc |
Warrants Issued To Purchase Of Common Stock
WarrantsIssuedToPurchaseOfCommonStock
|
1926656 | shares |
| CY2014Q3 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
3.50 | |
| CY2014Q3 | nnvc |
Aggregate Purchase Price Of Warrants
AggregatePurchasePriceOfWarrants
|
6743297 | USD |
| CY2015 | nnvc |
Number Of Common Stock To Be Issued Upon Conversion Of Warrants
NumberOfCommonStockToBeIssuedUponConversionOfWarrants
|
68592 | shares |
| CY2015Q2 | nnvc |
Fair Value Of Common Stock Warrant Issued During Period For Consulting Services
FairValueOfCommonStockWarrantIssuedDuringPeriodForConsultingServices
|
59675 | USD |
| CY2016Q1 | us-gaap |
Debt Conversion Converted Instrument Warrants Or Options Issued1
DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
|
571433 | shares |
| CY2016Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
3.50 | |
| CY2016Q1 | nnvc |
Adjustments To Additional Paid In Capital Warrant Issued For Debenture Interest
AdjustmentsToAdditionalPaidInCapitalWarrantIssuedForDebentureInterest
|
56115 | USD |
| CY2016Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
|
313155 | shares |
| CY2013Q3 | nnvc |
Fair Value Of Common Stock Warrant Issued During Period For Consulting Services
FairValueOfCommonStockWarrantIssuedDuringPeriodForConsultingServices
|
113696 | USD |
| CY2013Q3 | nnvc |
Adjustments To Additional Paid In Capital Warrant Issued For Debenture Interest
AdjustmentsToAdditionalPaidInCapitalWarrantIssuedForDebentureInterest
|
113696 | USD |
| CY2016 | us-gaap |
Conversion Of Stock Description
ConversionOfStockDescription
|
the converted value to common at a ratio of 1:3.5 | |
| CY2016 | nnvc |
Preferred Shares Issued As Compensation
PreferredSharesIssuedAsCompensation
|
882386 | USD |
| CY2015 | nnvc |
Preferred Shares Issued As Compensation
PreferredSharesIssuedAsCompensation
|
877234 | USD |
| CY2014 | nnvc |
Preferred Shares Issued As Compensation
PreferredSharesIssuedAsCompensation
|
2123014 | USD |
| CY2013Q3 | nnvc |
Warrants Issued To Purchase Of Common Stock
WarrantsIssuedToPurchaseOfCommonStock
|
35357 | shares |
| CY2014Q1 | nnvc |
Warrants Issued To Purchase Of Common Stock
WarrantsIssuedToPurchaseOfCommonStock
|
25000 | shares |
| CY2014Q1 | nnvc |
Warrants Issued To Purchase Of Common Stock
WarrantsIssuedToPurchaseOfCommonStock
|
75000 | shares |
| CY2014Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2014Q1 | nnvc |
Warrant Expiration Term
WarrantExpirationTerm
|
P5Y | |
| CY2013Q3 | nnvc |
Warrant Expiration Term
WarrantExpirationTerm
|
P5Y | |
| CY2013Q3 | nnvc |
Warrant Expiration Term
WarrantExpirationTerm
|
P5Y | |
| CY2016Q1 | nnvc |
Warrant Expiration Term
WarrantExpirationTerm
|
P3Y | |
| CY2015 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
0 | USD |
| CY2014 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
0 | USD |
| CY2016 | us-gaap |
Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
|
451258 | USD |
| CY2015 | us-gaap |
Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
|
266741 | USD |
| CY2014 | us-gaap |
Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
|
-114329 | USD |
| CY2016 | nnvc |
Allocation Of Proceeds From Private Placement To Derivative Liability Warrants
AllocationOfProceedsFromPrivatePlacementToDerivativeLiabilityWarrants
|
0 | USD |
| CY2015 | nnvc |
Allocation Of Proceeds From Private Placement To Derivative Liability Warrants
AllocationOfProceedsFromPrivatePlacementToDerivativeLiabilityWarrants
|
0 | USD |
| CY2014 | nnvc |
Allocation Of Proceeds From Private Placement To Derivative Liability Warrants
AllocationOfProceedsFromPrivatePlacementToDerivativeLiabilityWarrants
|
5740540 | USD |
| CY2014Q1 | nnvc |
Warrants Issued To Purchase Of Common Stock
WarrantsIssuedToPurchaseOfCommonStock
|
75000 | shares |
| CY2016 | us-gaap |
Salaries And Wages
SalariesAndWages
|
58910 | USD |
| CY2016 | us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
5740540 | USD |
| CY2016 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
7917713 | USD |
| CY2016 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i><u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Concentrations of Risk</u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Financial instruments that potentially subject us to a significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured institutions in excess of federally insured limits. The Company does not believe it is exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2016 | us-gaap |
Debt Instrument Redemption Description
DebtInstrumentRedemptionDescription
|
the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the “Redemption”). If the Company intends to repurchase the Debenture, and if the closing bid price of the common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the “Redemption Payment”, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of common Stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the common stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of common Stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of common Stock (the “Redemption Warrants”, and collectively with (i) – (iv), the “Redemption Payment”). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a “shelf” registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act. | |
| CY2014Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
6.05 | |
| CY2016Q2 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
5.25 | |
| CY2014Q1 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
76306 | shares |
| CY2014Q1 | nnvc |
Fair Value Of Common Stock Warrant Issued During Period For Consulting Services
FairValueOfCommonStockWarrantIssuedDuringPeriodForConsultingServices
|
135062 | USD |
| CY2016Q2 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
166667 | USD |
| CY2015Q2 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
166667 | USD |
| CY2016Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
6744014 | USD |
| CY2015Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
600895 | USD |
| CY2016Q2 | nnvc |
Deferred Interest Payable Noncurrent
DeferredInterestPayableNoncurrent
|
166667 | USD |
| CY2015Q2 | nnvc |
Deferred Interest Payable Noncurrent
DeferredInterestPayableNoncurrent
|
333333 | USD |
| CY2016Q2 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
6841190 | USD |
| CY2015Q2 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
11800327 | USD |
| CY2016Q2 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
87810145 | USD |
| CY2015Q2 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
85824614 | USD |
| CY2016 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
|
75000 | shares |
| CY2014 | nnvc |
Placement Agents Fees Related To Sale Of Common Shares And Warrants
PlacementAgentsFeesRelatedToSaleOfCommonSharesAndWarrants
|
1820360 | USD |
| CY2016Q2 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
2556241 | shares |
| CY2016 | us-gaap |
Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
|
-3515 | USD |
| CY2015 | us-gaap |
Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
|
150000 | USD |
| CY2014 | us-gaap |
Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
|
-150000 | USD |
| CY2016Q2 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
34326764 | USD |
| CY2016Q2 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | USD |
| CY2016Q2 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
20782598 | USD |
| CY2016Q2 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
5105024 | USD |
| CY2016Q2 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
8349142 | USD |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
-0.3400 | pure |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
-0.3400 | pure |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
-0.3400 | pure |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
0 | pure |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
-0.3700 | pure |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
-0.3700 | pure |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
-0.0610 | pure |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
0 | pure |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
0 | pure |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
-0.0618 | pure |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0 | pure |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0 | pure |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
0.4628 | pure |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
0.7100 | pure |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
0.7100 | pure |
| CY2016 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0 | pure |
| CY2015 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0 | pure |
| CY2014 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0 | pure |
